(E)-4,5,6,7-tetrachloro-N-{3-[2-(3,4-dimethoxyphenyl)ethenyl]phenyl}phthalimide | 1186335-66-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-4,5,6,7-tetrachloro-N-{3-[2-(3,4-dimethoxyphenyl)ethenyl]phenyl}phthalimide
• 英文别名: 3,4,5,6-tetrachloro-N-(3-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]phenyl)phthalimide；PPT-95；4,5,6,7-tetrachloro-2-[3-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]phenyl]isoindole-1,3-dione
• CAS: 1186335-66-9
• 化学式: C₂₄H₁₅Cl₄NO₄
• 分子量: 523.199
• InChiKey: ACLOSINMMSLCHB-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-4,5,6,7-tetrachloro-N-{3-[2-(3,4-dimethoxyphenyl)ethenyl]phenyl}phthalimide 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 (E)-4,5,6,7-tetrachloro-N-{3-[2-(3,4-dihydroxyphenyl)ethenyl]phenyl}phthalimide
  参考文献：
  名称：

  沙利度胺衍生的苯乙基苯基邻苯二甲酰亚胺类似物的抗流感活性

  摘要：

  源自猪的甲型流感病毒已在​​全世界引起大流行，甲型流感被认为是严重的全球健康问题。因此，非常需要靶向这些病毒的新型药物。甲型流感病毒表达对其转录和复制必不可少的RNA聚合酶，该酶包含PA，PB1和PB2亚基。我们从34种合成的来自沙利度胺的苯乙基苯基邻苯二甲酰亚胺类似物（PPT类似物）的筛选中鉴定出潜在的新型抗流感药。对于此筛选，我们使用了PA核酸内切酶抑制测定，PB2致病性决定域结合测定和抗A型流感病毒测定。发现三种PPT类似物PPT-65，PPT-66和PPT-67均能抑制PA核酸内切酶活性并延缓甲型流感的生长，表明它们的活性之间存在相关性。还发现PPT-28抑制甲型流感的生长。这四个类似物共有3,4-二羟基苯乙基。我们还讨论了3,4-二羟基苯乙基柔韧性可能在PA核酸内切酶抑制中起重要功能作用的可能性。另一个带有二甲氧基苯乙基的类似物PPT-62具有PB2致病性决定域结合活性，但没有抑

  DOI：

  10.1016/j.bmc.2010.05.035
• 作为产物：
  描述：

  (E)-3-[2-(3,4-dimethoxyphenyl)ethenyl]aniline 、 四氯苯二甲酸酐 反应 1.0h， 以73%的产率得到(E)-4,5,6,7-tetrachloro-N-{3-[2-(3,4-dimethoxyphenyl)ethenyl]phenyl}phthalimide
  参考文献：
  名称：

  Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists

  摘要：

  Liver X receptor (LXR) alpha/beta dual agonists are candidate medicaments for the treatment of metabolic syndrome, because their biological actions include increasing cholesterol efflux mediated by LXR beta. However, their clinical application is currently limited by their enhancing effect on triglyceride (TG) synthesis mediated by LXR alpha. Combination of an LXR alpha-selective antagonist with an LXR alpha/beta dual agonist may overcome this disadvantage. In the present work, structural development studies of phenethylphenyl phthalimide 9, which possesses LXR alpha/beta dual-antagonistic activity and alpha-glucosidase-inhibitory activity, led to the LXR alpha-selective antagonist 23f. Specific alpha-glucosidase inhibitors were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.066

文献信息

• Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide
  作者：Yuma Iwai、Hitoshi Takahashi、Dai Hatakeyama、Kazunori Motoshima、Minoru Ishikawa、Kazuyuki Sugita、Yuichi Hashimoto、Yuichi Harada、Shigeyuki Itamura、Takato Odagiri、Masato Tashiro、Yoshihisa Sei、Kentaro Yamaguchi、Takashi Kuzuhara

  DOI：10.1016/j.bmc.2010.05.035

  日期：2010.7

  subunits. We identified potential novel anti-influenza agents from a screen of 34 synthesized phenethylphenylphthalimide analogs derived from thalidomide (PPT analogs). For this screen we used a PA endonuclease inhibition assay, a PB2 pathogenicity-determinant domain-binding assay, and an anti-influenza A virus assay. Three PPT analogs, PPT-65, PPT-66, and PPT-67, were found to both inhibit PA endonuclease

  源自猪的甲型流感病毒已在​​全世界引起大流行，甲型流感被认为是严重的全球健康问题。因此，非常需要靶向这些病毒的新型药物。甲型流感病毒表达对其转录和复制必不可少的RNA聚合酶，该酶包含PA，PB1和PB2亚基。我们从34种合成的来自沙利度胺的苯乙基苯基邻苯二甲酰亚胺类似物（PPT类似物）的筛选中鉴定出潜在的新型抗流感药。对于此筛选，我们使用了PA核酸内切酶抑制测定，PB2致病性决定域结合测定和抗A型流感病毒测定。发现三种PPT类似物PPT-65，PPT-66和PPT-67均能抑制PA核酸内切酶活性并延缓甲型流感的生长，表明它们的活性之间存在相关性。还发现PPT-28抑制甲型流感的生长。这四个类似物共有3,4-二羟基苯乙基。我们还讨论了3,4-二羟基苯乙基柔韧性可能在PA核酸内切酶抑制中起重要功能作用的可能性。另一个带有二甲氧基苯乙基的类似物PPT-62具有PB2致病性决定域结合活性，但没有抑
• Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists
  作者：Kazunori Motoshima、Tomomi Noguchi-Yachide、Kazuyuki Sugita、Yuichi Hashimoto、Minoru Ishikawa

  DOI：10.1016/j.bmc.2009.05.066

  日期：2009.7

  Liver X receptor (LXR) alpha/beta dual agonists are candidate medicaments for the treatment of metabolic syndrome, because their biological actions include increasing cholesterol efflux mediated by LXR beta. However, their clinical application is currently limited by their enhancing effect on triglyceride (TG) synthesis mediated by LXR alpha. Combination of an LXR alpha-selective antagonist with an LXR alpha/beta dual agonist may overcome this disadvantage. In the present work, structural development studies of phenethylphenyl phthalimide 9, which possesses LXR alpha/beta dual-antagonistic activity and alpha-glucosidase-inhibitory activity, led to the LXR alpha-selective antagonist 23f. Specific alpha-glucosidase inhibitors were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.